Drugs / Y101D
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05028556 | Aug 2021 → Jul 2024 | cancer of unknown primary site | Wuhan YZY Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06266143 | Feb 2023 → Jan 2025 | pancreatic adenocarcinoma | Wuhan YZY Biopharma Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-12-12 | Wuhan YZY Biopharma Co., Ltd. | Results 科研进展 | JITC(IF: 12.5):友芝友生物双特异性抗体（抗TGF-β/PD-L1）在三阴性乳腺癌模型上取得科研新进展 yzybio.com ↗
本研究发现，BiTP的这种改善了肿瘤微环境的作用提升了抗肿瘤活性，在TNBC中具有优于单抗的抗肿瘤活性，表明BiTP是一种对于TNBC治疗可能有前途的药物。 |
| 2022-12-07 | Wuhan YZY Biopharma Co., Ltd. | Regulatory 临床试验许可：PD-L1/TGF-β双特异性抗体（Y101D）联合用药一线治疗胰腺癌临床试验获得许可 yzybio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-12-12 | Wuhan YZY Biopharma Co., Ltd. | 科研进展 | JITC(IF: 12.5):友芝友生物双特异性抗体（抗TGF-β/PD-L1）在三阴性乳腺癌模型上取得科研新进展 yzybio.com ↗ |
| 2022-12-07 | Wuhan YZY Biopharma Co., Ltd. | 临床试验许可：PD-L1/TGF-β双特异性抗体（Y101D）联合用药一线治疗胰腺癌临床试验获得许可 yzybio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y101D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06266143 ↗ |
| Route | Intravenous | “Y101D was administered intravenously every 2 weeks (Q2W) at 1, 3, 10, 20, and 30 mg/kg.” PMID 42104927 ↗ May 2026 |